Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DIFFERIN vs AKRINOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Adapalene is a retinoid-like compound that binds to retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating gene expression and normalizing differentiation and proliferation of follicular epithelial cells, reducing comedogenesis and inflammation.
Not available; likely a combination product with antihistaminic and sympathomimetic actions.
FDA-approved for the topical treatment of acne vulgaris in patients aged 12 and older. Off-label uses include treatment of photodamage, keratosis pilaris, and actinic keratoses.
Allergic rhinitis,Nasal congestion
Apply a thin layer of 0.1% gel or cream to affected areas once daily in the evening.
Adults: 100 mg orally twice daily.
Terminal elimination half-life is approximately 14–22 hours; steady-state is achieved within 3–5 days.
3-4 hours (prolonged to 8-12 hours in renal impairment; no dose adjustment typically needed unless Cr Cl <30 m L/min).
Adapalene is minimally metabolized in the skin; systemic absorption is low. Any absorbed drug is primarily metabolized in the liver via cytochrome P450 enzymes, likely CYP2C9 and CYP3A4, and excreted in bile as metabolites.
Not available; components may be metabolized via hepatic CYP enzymes.
Primarily biliary/fecal (>95%) as unchanged drug and metabolites; renal excretion is negligible.
Primarily renal (80-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal (5-10%).
Highly protein-bound (>99%), mainly to plasma albumin and lipoproteins.
99.5% (primarily to albumin; also to α1-acid glycoprotein).
Large volume of distribution (~14–16 L/kg), indicating extensive tissue binding and distribution.
0.10-0.17 L/kg (low, indicating limited extravascular distribution; primarily in central compartment).
Topical absorption is minimal (<5% of applied dose); systemic bioavailability is negligible.
Oral: 3-5% (extensive first-pass metabolism); IV: 100%.
No dose adjustment required for renal impairment.
GFR 30-59 m L/min: 50 mg daily; GFR <30 m L/min: 50 mg every other day.
No dose adjustment required for hepatic impairment.
Child-Pugh A: 100 mg twice daily; Child-Pugh B: 50 mg twice daily; Child-Pugh C: 50 mg daily.
Approved for acne vulgaris in patients aged 12 years and older: apply 0.1% gel or cream once daily. Safety and efficacy in children under 12 not established.
Children (1-12 years): 2 mg/kg orally twice daily, max 100 mg/dose.
No specific dose adjustment; use with caution due to increased risk of skin irritation and dryness in elderly skin.
Adults >65 years: initiate at 50 mg twice daily, titrate to 100 mg twice daily as tolerated.
None.
None
Avoid application to cuts, abrasions, eczematous, or sunburned skin.,Avoid excessive exposure to sunlight and UV light; use sunscreen.,Possible local skin reactions: erythema, scaling, dryness, burning, pruritus; dose reduction or interruption may be necessary.,Use caution in patients with eczema.,Not for oral or ophthalmic use.
Use with caution in patients with hypertension,Avoid in patients with severe coronary artery disease
Hypersensitivity to adapalene or any component of the formulation. Not for use in patients with known sensitivity to retinoids.
Hypersensitivity to any component,Severe hypertension,Concomitant use with MAO inhibitors
No significant food interactions. However, high-fat meals may slightly increase systemic absorption; unlikely to be clinically relevant.
No known food interactions with topical naftifine. No dietary restrictions required.
Pregnancy Category C. Animal studies show teratogenicity at high oral doses; topical exposure has minimal systemic absorption. First trimester: risk cannot be ruled out. Second/third trimester: limited data, avoid use. No adequate human studies.
FDA Pregnancy Category D. First trimester: risk of CNS defects and spontaneous abortion. Second/third trimester: risk of premature closure of ductus arteriosus, oligohydramnios, renal dysfunction, necrotizing enterocolitis, periventricular hemorrhage, and pulmonary hypertension.
Not recommended. Excretion into human milk unknown; low systemic absorption likely but risk to infant cannot be excluded. M/P ratio not established.
Contraindicated during breastfeeding. M/P ratio not determined due to contraindication. Excreted into breast milk; potential for serious adverse effects in infant.
Discontinue use. No dosage adjustment studies; topical application is contraindicated regardless of pharmacokinetic changes.
No established safe dose. Generally contraindicated during pregnancy. If used, lowest effective dose and shortest duration. Avoid after 20 weeks gestation.
Use a pea-sized amount for entire face to avoid irritation. Initiate with lower concentration (0.1% gel) for sensitive skin. Combination with benzoyl peroxide or topical antibiotics may enhance efficacy. Sunscreen is mandatory due to photosensitization. Do not apply to broken, eczematous, or sunburned skin.
AKRINOL is a topical antifungal (naftifine) that inhibits squalene epoxidase, effective against dermatophytes. Apply once daily for 2-4 weeks. Avoid occlusive dressings. Monitor for local irritation or allergic contact dermatitis.
Apply a thin layer once daily at bedtime to clean, dry skin.,Avoid excessive washing or using abrasive cleansers.,Use oil-free, non-comedogenic moisturizers and cosmetics.,Expect initial worsening of acne (retinoid reaction) which resolves in 4-6 weeks.,Sun protection (SPF 30+) and protective clothing are essential daily.,Minimize exposure to extreme wind or cold.,If pregnant, planning pregnancy, or breastfeeding, consult physician before use.,Keep away from eyes, mouth, nasal angles, and mucous membranes.
Apply a thin layer to the affected area once daily, usually for 2 to 4 weeks.,Wash hands before and after application unless treating the hands.,Do not cover the treated area with bandages or wraps unless directed.,Avoid contact with eyes, nose, mouth, or broken skin. If contact occurs, rinse with water.,Notify your doctor if condition worsens, does not improve within 4 weeks, or if severe irritation or allergic reaction develops.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DIFFERIN vs AKRINOL, answered by our medical review team.
DIFFERIN is a Topical Retinoid that works by Adapalene is a retinoid-like compound that binds to retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating gene expression and normalizing differentiation and proliferation of follicular epithelial cells, reducing comedogenesis and inflammation.. AKRINOL is a Topical Retinoid that works by Not available; likely a combination product with antihistaminic and sympathomimetic actions.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DIFFERIN and AKRINOL depend on the specific clinical indication. These are both Topical Retinoid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DIFFERIN is: Apply a thin layer of 0.1% gel or cream to affected areas once daily in the evening.. The standard adult dose of AKRINOL is: Adults: 100 mg orally twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DIFFERIN and AKRINOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DIFFERIN is classified as Category C. Pregnancy Category C. Animal studies show teratogenicity at high oral doses; topical exposure has minimal systemic absorption. First trimester: risk cannot be ruled out. Second/thi. AKRINOL is classified as Category C. FDA Pregnancy Category D. First trimester: risk of CNS defects and spontaneous abortion. Second/third trimester: risk of premature closure of ductus arteriosus, oligohydramnios, re. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.